Q32 Bio Sells Complement Inhibitor ADX-097

Stock Information for Journey Medical Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Journey Medical Corporation

Akebia Announces Establishment of Rare Kidney Disease Pipeline
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.